Ignyta Stock Price, News & Analysis (NASDAQ:RXDX)

$15.75 0.85 (5.70 %)
(As of 11/21/2017 01:27 AM ET)
Previous Close$14.90
Today's Range$14.85 - $15.90
52-Week Range$4.60 - $18.30
Volume1.16 million shs
Average Volume817,151 shs
Market Capitalization$988.44 million
P/E RatioN/A
Dividend YieldN/A
Beta2.11

About Ignyta (NASDAQ:RXDX)

Ignyta logoIgnyta, Inc. is a biotechnology company. The Company is focused on precision medicine in oncology. The Company is pursuing an integrated therapeutic (Rx) and companion diagnostic (Dx) strategy for treating cancer patients. The Company's pipeline includes various compounds, such as entrectinib, RXDX-105, taladegib and RXDX-106. Entrectinib is an orally bioavailable, central nervous system (CNS)-active, small molecule tyrosine kinase inhibitor directed to the tropomyosin receptor kinase (TRK) family of tyrosine kinase receptors (TRKA, TRKB and TRKC), ROS1 and anaplastic lymphoma kinase (ALK) proteins. RXDX-105 is an orally bioavailable, vascular endothelial growth factor receptor (VEGFR)-sparing, small molecule tyrosine kinase inhibitor of rearranged during transfection (RET). Taladegib is an orally bioavailable, small molecule hedgehog/smoothened antagonist. RXDX-106 is a pseudo-irreversible, small molecule inhibitor of TYRO3, AXL and MER (collectively TAM), and c-MET.


Industry, Sector and Symbol:
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Sector: Medical
  • Symbol: NASDAQ:RXDX
  • CUSIP: N/A
  • Web: www.ignyta.com
Debt:
  • Debt-to-Equity Ratio: 0.34%
  • Current Ratio: 6.07%
  • Quick Ratio: 6.07%
Sales & Book Value:
  • Annual Sales: $150,000.00
  • Price / Sales: 6,965.70
  • Book Value: $2.28 per share
  • Price / Book: 6.91
Profitability:
  • Trailing EPS: ($2.70)
  • Net Income: $-103,630,000.00
  • Return on Equity: -140.88%
  • Return on Assets: -83.79%
Misc:
  • Employees: 112
  • Outstanding Shares: 66,340,000
 

Frequently Asked Questions for Ignyta (NASDAQ:RXDX)

What is Ignyta's stock symbol?

Ignyta trades on the NASDAQ under the ticker symbol "RXDX."

How were Ignyta's earnings last quarter?

Ignyta, Inc. (NASDAQ:RXDX) announced its quarterly earnings results on Tuesday, November, 7th. The biopharmaceutical company reported ($0.51) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.54) by $0.03. View Ignyta's Earnings History.

Where is Ignyta's stock going? Where will Ignyta's stock price be in 2017?

4 brokers have issued twelve-month target prices for Ignyta's shares. Their predictions range from $20.00 to $31.00. On average, they expect Ignyta's stock price to reach $25.25 in the next twelve months. View Analyst Ratings for Ignyta.

What are Wall Street analysts saying about Ignyta stock?

Here are some recent quotes from research analysts about Ignyta stock:

  • 1. According to Zacks Investment Research, "Ignyta, Inc. is a biotechnology company. It develops precision medicine with integrated Rx/Dx solutions for cancer patients. The company focuses on the development of RXDX-101, its proprietary oral tyrosine kinase inhibitor that targets solid tumor indications, and advancing its novel Spark discovery programs that leverage its proprietary cancer genomic and epigenomic knowledge bases. Ignyta, Inc. is based in San Diego, California. " (11/14/2017)
  • 2. Cantor Fitzgerald analysts commented, "Entrectinib has received Priority Medicines (PRIME) designation from the European Medicines Agency (EMA), for NTRK fusion-positive solid tumors, primarily based on STARTRK-2 results." (10/17/2017)
  • 3. Jefferies Group LLC analysts commented, "ENA preclinical posters on RXDX-106 showed encouraging activity in both immuno-oncologic modulation and direct tumor targeting. These initial data support further development of ‘106 and we would look for more details at Dec 1 conference call. Incremental preclinical data of ‘105 and entrectinib were also presented." (11/30/2016)

Who are some of Ignyta's key competitors?

Who are Ignyta's key executives?

Ignyta's management team includes the folowing people:

  • Jonathan E. Lim M.D., Chairman of the Board, President, Chief Executive Officer, Co-Founder (Age 45)
  • Jacob M. Chacko M.D., Chief Financial Officer (Age 38)
  • Zachary Hornby, Chief Operating Officer (Age 38)
  • Valerie Harding Start Ph.D., Senior Vice President - Chemistry, Manufacturing, and Controls (Age 57)
  • Christian V. Kuhlen M.D. Esq., General Counsel, Secretary (Age 44)
  • William R. McCarthy, Chief Business Officer (Age 45)
  • Pratik S. Multani M.D., Chief Medical Officer (Age 50)
  • James A. Bristol Ph.D., Independent Director (Age 70)
  • Alexander W. Casdin, Independent Director (Age 49)
  • Heinrich Dreismann Ph.D., Independent Director (Age 64)

Who owns Ignyta stock?

Ignyta's stock is owned by many different of institutional and retail investors. Top institutional investors include Victory Capital Management Inc. (5.00%), Emerald Advisers Inc. PA (2.75%), JPMorgan Chase & Co. (2.07%), Emerald Mutual Fund Advisers Trust (2.06%), Wells Fargo & Company MN (1.49%) and Pier Capital LLC (0.81%). Company insiders that own Ignyta stock include Alexander W Casdin, Jacob Chacko, James A Bristol, James L Freddo and Jonathan E Lim. View Institutional Ownership Trends for Ignyta.

Who sold Ignyta stock? Who is selling Ignyta stock?

Ignyta's stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Emerald Advisers Inc. PA, Pier Capital LLC, Dimensional Fund Advisors LP, California State Teachers Retirement System and Emerald Mutual Fund Advisers Trust. View Insider Buying and Selling for Ignyta.

Who bought Ignyta stock? Who is buying Ignyta stock?

Ignyta's stock was acquired by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, JPMorgan Chase & Co., Greenwoods Asset Management Ltd, American Century Companies Inc., Ameriprise Financial Inc., OxFORD Asset Management LLP, Nationwide Fund Advisors and Allianz Asset Management GmbH. Company insiders that have bought Ignyta stock in the last two years include Alexander W Casdin, Jacob Chacko, James A Bristol, James L Freddo and Jonathan E Lim. View Insider Buying and Selling for Ignyta.

How do I buy Ignyta stock?

Shares of Ignyta can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ignyta's stock price today?

One share of Ignyta stock can currently be purchased for approximately $15.75.

How big of a company is Ignyta?

Ignyta has a market capitalization of $988.44 million and generates $150,000.00 in revenue each year. The biopharmaceutical company earns $-103,630,000.00 in net income (profit) each year or ($2.70) on an earnings per share basis. Ignyta employs 112 workers across the globe.

How can I contact Ignyta?

Ignyta's mailing address is 4545 TOWNE CENTRE COURT, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-255-5959.


MarketBeat Community Rating for Ignyta (NASDAQ RXDX)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  179 (Vote Outperform)
Underperform Votes:  83 (Vote Underperform)
Total Votes:  262
MarketBeat's community ratings are surveys of what our community members think about Ignyta and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Ignyta (NASDAQ:RXDX)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 0 Hold Ratings, 4 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $25.25 (60.32% upside)

Consensus Price Target History for Ignyta (NASDAQ:RXDX)

Price Target History for Ignyta (NASDAQ:RXDX)

Analysts' Ratings History for Ignyta (NASDAQ:RXDX)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/20/2017SunTrust Banks, Inc.Initiated CoverageBuyN/AView Rating Details
11/14/2017Cantor FitzgeraldSet Price TargetBuy$23.00N/AView Rating Details
10/18/2017Ladenburg Thalmann Financial ServicesBoost Price Target$20.25 -> $31.00N/AView Rating Details
10/12/2017J P Morgan Chase & CoReiterated RatingBuy$18.00 -> $20.00N/AView Rating Details
6/22/2017Jefferies Group LLCReiterated RatingBuy -> Buy$27.00HighView Rating Details
8/10/2016Piper Jaffray CompaniesLower Price TargetOverweight$32.00 -> $20.00N/AView Rating Details
7/12/2016Credit Suisse GroupReiterated RatingBuyN/AView Rating Details
5/12/2016Leerink SwannReiterated RatingBuyN/AView Rating Details
(Data available from 11/21/2015 forward)

Earnings

Earnings History and Estimates Chart for Ignyta (NASDAQ:RXDX)

Earnings by Quarter for Ignyta (NASDAQ:RXDX)

Earnings History by Quarter for Ignyta (NASDAQ RXDX)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2017Q3 2017($0.54)($0.51)ViewN/AView Earnings Details
8/8/2017Q2 2017($0.63)($0.56)ViewN/AView Earnings Details
5/1/2017Q1 2017($0.69)($0.96)ViewN/AView Earnings Details
11/7/2016Q3 2016($0.67)($0.56)ViewN/AView Earnings Details
5/10/2016Q1($0.68)($0.79)ViewListenView Earnings Details
3/14/2016Q415($0.57)($1.32)ViewN/AView Earnings Details
11/9/2015Q315($0.60)($0.49)ViewN/AView Earnings Details
8/10/2015Q215($0.65)($0.51)ViewListenView Earnings Details
5/11/2015Q115($0.79)($1.15)ViewListenView Earnings Details
4/14/2015($0.79)($1.05)ViewN/AView Earnings Details
3/17/2015Q414($0.59)($2.18)ViewN/AView Earnings Details
11/7/2014Q314$0.01($0.55)$215.50 millionViewN/AView Earnings Details
8/12/2014($0.26)($0.28)$0.15 millionViewN/AView Earnings Details
5/12/2014($0.37)($0.28)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Ignyta (NASDAQ:RXDX)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20171($0.69)($0.69)($0.69)
Q3 20171($0.53)($0.53)($0.53)
Q4 20171($0.46)($0.46)($0.46)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Ignyta (NASDAQ:RXDX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Ignyta (NASDAQ RXDX)

Insider Ownership Percentage: 13.08%
Institutional Ownership Percentage: 71.82%
Insider Trades by Quarter for Ignyta (NASDAQ:RXDX)
Institutional Ownership by Quarter for Ignyta (NASDAQ:RXDX)

Insider Trades by Quarter for Ignyta (NASDAQ RXDX)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/15/2016James A BristolDirectorBuy5,000$5.65$28,250.00View SEC Filing  
5/4/2016Alexander W CasdinDirectorBuy232,000$6.25$1,450,000.00View SEC Filing  
3/17/2016Jacob ChackoCFOBuy10,000$5.64$56,400.00View SEC Filing  
3/17/2016James L FreddoDirectorBuy3,000$5.39$16,170.00View SEC Filing  
3/17/2016Jonathan E LimCEOBuy24,852$5.51$136,934.52View SEC Filing  
12/16/2015Jacob ChackoCFOBuy1,500$12.00$18,000.00View SEC Filing  
8/20/2015City Hill Venture Partners I,major shareholderBuy8,480$12.90$109,392.00View SEC Filing  
6/15/2015Robert WildVPBuy1,200$16.35$19,620.00View SEC Filing  
3/20/2015Jonathan E LimCEOBuy20,000$9.01$180,200.00View SEC Filing  
3/17/2015Alexander W CasdinDirectorBuy408,750$10.00$4,087,500.00View SEC Filing  
11/24/2014Jacob ChackoCFOBuy1,598$6.46$10,323.08View SEC Filing  
8/19/2014Jacob ChackoCFOBuy1,840$7.53$13,855.20View SEC Filing  
8/15/2014Jonathan E LimCEOBuy5,000$7.60$38,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Ignyta (NASDAQ RXDX)

Source:
DateHeadline
Ignyta, Inc. (RXDX) Earns Buy Rating from Analysts at SunTrust Banks, Inc.Ignyta, Inc. (RXDX) Earns Buy Rating from Analysts at SunTrust Banks, Inc.
www.americanbankingnews.com - November 20 at 4:14 PM
New Research: Key Drivers of Growth for Scana, Goldman Sachs Group, FMC, DineEquity, Ignyta, and Barnes & Noble — Factors of Influence, Major Initiatives and Sustained ProductionNew Research: Key Drivers of Growth for Scana, Goldman Sachs Group, FMC, DineEquity, Ignyta, and Barnes & Noble — Factors of Influence, Major Initiatives and Sustained Production
finance.yahoo.com - November 20 at 9:29 AM
Ignyta, Inc. (RXDX) Stock Rating Upgraded by Zacks Investment ResearchIgnyta, Inc. (RXDX) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - November 14 at 7:50 AM
Jefferies Group Analysts Raise Earnings Estimates for Ignyta, Inc. (RXDX)Jefferies Group Analysts Raise Earnings Estimates for Ignyta, Inc. (RXDX)
www.americanbankingnews.com - November 13 at 2:14 AM
Ignyta to Present at the Jefferies 2017 London Healthcare ConferenceIgnyta to Present at the Jefferies 2017 London Healthcare Conference
finance.yahoo.com - November 12 at 12:34 PM
Ignyta (RXDX) Announces New Data Highlighting Immune Modulation of RXDX-106 at SITCIgnyta (RXDX) Announces New Data Highlighting Immune Modulation of RXDX-106 at SITC
www.streetinsider.com - November 9 at 12:51 PM
Ignyta Announces Third Quarter 2017 Company Highlights and Financial ResultsIgnyta Announces Third Quarter 2017 Company Highlights and Financial Results
finance.yahoo.com - November 9 at 12:50 PM
Ignyta reports 3Q lossIgnyta reports 3Q loss
finance.yahoo.com - November 9 at 12:50 PM
Ignyta Announces New Data Highlighting Immune Modulation of RXDX-106 at the Society for Immunotherapy of Cancer (SITC) MeetingIgnyta Announces New Data Highlighting Immune Modulation of RXDX-106 at the Society for Immunotherapy of Cancer (SITC) Meeting
finance.yahoo.com - November 9 at 12:50 PM
Ignyta, Inc. (RXDX) Releases  Earnings Results, Beats Estimates By $0.03 EPSIgnyta, Inc. (RXDX) Releases Earnings Results, Beats Estimates By $0.03 EPS
www.americanbankingnews.com - November 8 at 6:27 PM
Ignyta, Inc. (RXDX) Expected to Post Earnings of -$0.56 Per ShareIgnyta, Inc. (RXDX) Expected to Post Earnings of -$0.56 Per Share
www.americanbankingnews.com - November 7 at 5:28 AM
Ignyta, Inc. (RXDX) Given Average Rating of "Buy" by BrokeragesIgnyta, Inc. (RXDX) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - November 6 at 10:34 AM
Ignyta to Present at Credit Suisse 26th Annual Healthcare ConferenceIgnyta to Present at Credit Suisse 26th Annual Healthcare Conference
finance.yahoo.com - November 1 at 8:25 PM
Ignyta (RXDX) Prices 10M Share Common Offering at $10/Sh - StreetInsider.comIgnyta (RXDX) Prices 10M Share Common Offering at $10/Sh - StreetInsider.com
www.streetinsider.com - October 22 at 6:27 AM
Ignyta (RXDX) Pricies 10M Share Common Offering at $10/Sh - StreetInsider.comIgnyta (RXDX) Pricies 10M Share Common Offering at $10/Sh - StreetInsider.com
www.streetinsider.com - October 20 at 4:46 PM
UPDATE: Ignyta, Inc (RXDX) PT Raised to $31 at Ladenburg Thalmann - StreetInsider.comUPDATE: Ignyta, Inc (RXDX) PT Raised to $31 at Ladenburg Thalmann - StreetInsider.com
www.streetinsider.com - October 20 at 4:46 PM
Ignyta (RXDX) Prices 10M Share Common Offering at $10/ShIgnyta (RXDX) Prices 10M Share Common Offering at $10/Sh
www.streetinsider.com - October 20 at 7:46 AM
Ignyta Announces Pricing of Public Offering of Common StockIgnyta Announces Pricing of Public Offering of Common Stock
finance.yahoo.com - October 20 at 7:46 AM
Harry Boxer’s three biotech-stock breakouts to watchHarry Boxer’s three biotech-stock breakouts to watch
finance.yahoo.com - October 19 at 8:21 AM
Analyst: Entrectinibs Potential Gives Ignytas Stock 116% UpsideAnalyst: Entrectinib's Potential Gives Ignyta's Stock 116% Upside
finance.yahoo.com - October 19 at 8:21 AM
Ignyta Announces Proposed Public Offering of Common StockIgnyta Announces Proposed Public Offering of Common Stock
finance.yahoo.com - October 19 at 8:21 AM
Corporate News Blog - EMA Grants PRIME Designation to Ignytas Entrectinib in NTRK Fusion-Positive Solid TumorsCorporate News Blog - EMA Grants PRIME Designation to Ignyta's Entrectinib in NTRK Fusion-Positive Solid Tumors
finance.yahoo.com - October 19 at 8:21 AM
Ladenburg Thalmann Financial Services Boosts Ignyta, Inc. (RXDX) Price Target to $31.00Ladenburg Thalmann Financial Services Boosts Ignyta, Inc. (RXDX) Price Target to $31.00
www.americanbankingnews.com - October 18 at 5:10 PM
Ignyta, Inc. (RXDX) Downgraded by Zacks Investment ResearchIgnyta, Inc. (RXDX) Downgraded by Zacks Investment Research
www.americanbankingnews.com - October 18 at 6:08 AM
Interim Analysis of Ignytas Entrectinib Suggests Potential Best-in-Class Profile as a First-Line Targeted Therapy ... - Business Wire (press release)Interim Analysis of Ignyta's Entrectinib Suggests Potential Best-in-Class Profile as a First-Line Targeted Therapy ... - Business Wire (press release)
www.businesswire.com - October 18 at 1:36 AM
Interim Analysis of Ignyta’s Entrectinib Suggests Potential Best-in-Class Profile as a First-Line Targeted Therapy in Patients With ROS1-Positive Non-Small Cell Lung CancerInterim Analysis of Ignyta’s Entrectinib Suggests Potential Best-in-Class Profile as a First-Line Targeted Therapy in Patients With ROS1-Positive Non-Small Cell Lung Cancer
finance.yahoo.com - October 18 at 1:36 AM
Tiny Ignytas Lung Cancer Drug Bested Pfizers. Probably. Will We Ever Know For Sure?Tiny Ignyta's Lung Cancer Drug Bested Pfizer's. Probably. Will We Ever Know For Sure?
finance.yahoo.com - October 18 at 1:36 AM
Ignyta (RXDX) Announces EMA Prime Designation for Entrectinib in ... - StreetInsider.comIgnyta (RXDX) Announces EMA Prime Designation for Entrectinib in ... - StreetInsider.com
www.streetinsider.com - October 17 at 8:35 PM
Ignyta (RXDX) Announces EMA Prime Designation for Entrectinib in NTRK Fusion-Positive Solid TumorsIgnyta (RXDX) Announces EMA Prime Designation for Entrectinib in NTRK Fusion-Positive Solid Tumors
www.streetinsider.com - October 17 at 3:29 PM
Ignyta Receives European Medicines Agency Prime Designation for Entrectinib in NTRK Fusion-Positive Solid TumorsIgnyta Receives European Medicines Agency Prime Designation for Entrectinib in NTRK Fusion-Positive Solid Tumors
finance.yahoo.com - October 17 at 3:29 PM
Cantor Fitzgerald Reaffirms "Buy" Rating for Ignyta, Inc. (RXDX)Cantor Fitzgerald Reaffirms "Buy" Rating for Ignyta, Inc. (RXDX)
www.americanbankingnews.com - October 17 at 10:08 AM
J P Morgan Chase & Co Reiterates Buy Rating for Ignyta, Inc. (RXDX)J P Morgan Chase & Co Reiterates Buy Rating for Ignyta, Inc. (RXDX)
www.americanbankingnews.com - October 14 at 10:12 PM
Ignyta, Inc. (RXDX) Receives Average Rating of "Buy" from AnalystsIgnyta, Inc. (RXDX) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - October 12 at 1:18 PM
Ignyta Announces New Data Highlighting Immuno-Oncological Efficacy of RXDX-106 at 2017 AACR Tumor ... - Business Wire (press release)Ignyta Announces New Data Highlighting Immuno-Oncological Efficacy of RXDX-106 at 2017 AACR Tumor ... - Business Wire (press release)
www.businesswire.com - October 3 at 11:54 AM
Ignyta Announces New Data Highlighting Immuno-Oncological Efficacy of RXDX-106 at 2017 AACR Tumor Immunology and Immunotherapy MeetingIgnyta Announces New Data Highlighting Immuno-Oncological Efficacy of RXDX-106 at 2017 AACR Tumor Immunology and Immunotherapy Meeting
finance.yahoo.com - October 3 at 11:54 AM
Ignyta Announces Updated Data on Entrectinib in ROS1 NSCLC to Be Presented at the IASLC 18th World Conference on Lung CancerIgnyta Announces Updated Data on Entrectinib in ROS1 NSCLC to Be Presented at the IASLC 18th World Conference on Lung Cancer
www.businesswire.com - September 28 at 8:10 PM
Ignyta (RXDX) Says Updated Data on Entrectinib in ROS1 NSCLC to Be Presented at IASLC - StreetInsider.comIgnyta (RXDX) Says Updated Data on Entrectinib in ROS1 NSCLC to Be Presented at IASLC - StreetInsider.com
www.streetinsider.com - September 27 at 9:34 PM
Cantor Fitzgerald Reiterates "Buy" Rating for Ignyta, Inc. (RXDX)Cantor Fitzgerald Reiterates "Buy" Rating for Ignyta, Inc. (RXDX)
www.americanbankingnews.com - September 27 at 4:16 PM
Ignyta to Present at Cantor Fitzgerald 2017 Global Healthcare ConferenceIgnyta to Present at Cantor Fitzgerald 2017 Global Healthcare Conference
finance.yahoo.com - September 20 at 8:37 AM
Ignyta to Present at the Ladenburg Thalmann 2017 Healthcare ConferenceIgnyta to Present at the Ladenburg Thalmann 2017 Healthcare Conference
finance.yahoo.com - September 19 at 7:21 AM
Ignyta: A Value-Catalyst Play - Seeking AlphaIgnyta: A Value-Catalyst Play - Seeking Alpha
seekingalpha.com - September 13 at 4:43 PM
BRIEF-Ignyta provides update on entrectinib and RXDX-105 at the ESMO 2017 CongressBRIEF-Ignyta provides update on entrectinib and RXDX-105 at the ESMO 2017 Congress
www.reuters.com - September 12 at 9:25 AM
Ignyta Provides Update on Entrectinib and RXDX-105 at the ESMO 2017 CongressIgnyta Provides Update on Entrectinib and RXDX-105 at the ESMO 2017 Congress
finance.yahoo.com - September 12 at 9:25 AM
Ignyta Announces Presentation of New Phase 1B Clinical Data on RXDX-105 in RET Fusion-Positive NSCLC at ESMO 2017 CongressIgnyta Announces Presentation of New Phase 1B Clinical Data on RXDX-105 in RET Fusion-Positive NSCLC at ESMO 2017 Congress
finance.yahoo.com - September 8 at 7:56 AM
Ignytas (RXDX) Buy Rating Reaffirmed at Cantor FitzgeraldIgnyta's (RXDX) Buy Rating Reaffirmed at Cantor Fitzgerald
www.americanbankingnews.com - September 7 at 3:26 PM
Ignyta (RXDX) Offers Regulatory Update on Entrectinib ROS1 Lung Cancer Development ProgramIgnyta (RXDX) Offers Regulatory Update on Entrectinib ROS1 Lung Cancer Development Program
www.streetinsider.com - September 7 at 8:40 AM
Ignyta Provides Regulatory Update on Entrectinib ROS1 Lung Cancer Development ProgramIgnyta Provides Regulatory Update on Entrectinib ROS1 Lung Cancer Development Program
finance.yahoo.com - September 7 at 8:40 AM
Implied Volatility Surging for Ignyta (RXDX) Stock OptionsImplied Volatility Surging for Ignyta (RXDX) Stock Options
www.zacks.com - September 6 at 7:56 AM
Ignyta to Host Conference Call and Webcast on Entrectinib ROS1 Lung Cancer Update on September 6, 2017Ignyta to Host Conference Call and Webcast on Entrectinib ROS1 Lung Cancer Update on September 6, 2017
finance.yahoo.com - August 31 at 9:37 AM
Contrasting Fate Therapeutics (FATE) & Ignyta (RXDX)Contrasting Fate Therapeutics (FATE) & Ignyta (RXDX)
www.americanbankingnews.com - August 19 at 4:32 PM

Social Media

Financials

Chart

Ignyta (NASDAQ RXDX) Chart for Tuesday, November, 21, 2017
Loading chart…

This page was last updated on 11/21/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.